Thorsten Siess
CTO @ Abiomed
Thorsten Siess is a Series A investor at Abiomed focused on Health Care and Life Science. Thorsten Siess
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Thorsten Siess invests in
Stages Thorsten Siess invests in
Countries Thorsten Siess invests in
Investment Focus
Industry
- Health Care 1 (100%)
- Life Science 1 (100%)
- Medical Device 1 (100%)
- Personal Health 1 (100%)
- Emergency Medicine 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Protembis
|
ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation. | $10M / Series A / Sep 13, 2018 |
Co-Investors
About Abiomed
Abiomed is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's productsare used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.
Abiomed Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chuck Simonton
Chief Medical Officer, Vice President of Global Clinical & Medical Affairs
|
|||
|
David Lederman
Founder
|
|||
|
Noam Josephy
Director of Academic Research
|
|||
|
Ryan Orizondo
Senior Mechanical Engineer II
|
|||
|
Thorsten Siess
CTO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Thorsten Siess invest in?
Thorsten Siess invests primarily in Health Care, Life Science and Medical Device startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Thorsten Siess last invest?
The most recent investment recorded for Thorsten Siess closed in Sep 2018. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
